Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus;Revisión de la farmacología, eficacia y seguridad de linagliptina en el tratamiento de pacientes con diabetes mellitus tipo 2

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 358-367

  Neumiller, Joshua J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4 inhibitor; Linagliptin

Indexed keywords

ALOGLIPTIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

DIET RESTRICTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PRIORITY JOURNAL; PUBLICATION; REVIEW; UNITED STATES;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; HUMANS; PURINES; QUINAZOLINES;

EID: 84858011452     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q522     Document Type: Review

References (45)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.DOI 10.1016/j.diabres.2009.10.007
2. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003;299:853-5.DOI 10.1126/science.1079857
3. US Department of Health and Human Services. National Institute of Dia- betes and Digestive and Kidney Diseases. National diabetes statistics, 2011 fact sheet. http://diabetes.niddk.nih.gov/dm/pubs/statistics/ (ac- cessed 2011 Jul 23).
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase- 4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705. DOI 10.1016/S0140-6736(06)69705-5
5. Brown JC, Dryburgh JR, Ross SA, Dupré J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 1975;31:487-532.
6. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like pep-tide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-4. DOI 10.1016/S0140-6736(87)91194-9
7. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydroly- ses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.DOI 10.1111/j.1432-1033.1993.tb17986.x
8. Freeman JS. The pathophysiologic role of incretins. J Am Osteopath As- soc 2007;107(suppl 3):S6-9.
9. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004;53(suppl 3):S190-6. DOI 10.2337/diabetes.53.suppl_3.S190
10. American Diabetes Association. Standards of medical care in dia- betes-2011. Diabetes Care 2011;34(suppl 1):S11-61.DOI 10.2337/dc11-S011
11. Rydén L, Standl E, Bartnik M, et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre- diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardi- ology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136. DOI 10.1093/eurheartj/ehl260
12. Rodbard HW, Davidson JA, Garber AJ, Handelsman Y, Lebovitz H, Moghissi ES. Statement by an American Association of Clinical Endocri- nologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15: 540-59.
13. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Associa- tion; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initia- tion and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Dia- betes. Diabetes Care 2009;32:193-203. DOI 10.2337/dc08-9025
14. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf (accessed 2011 Jul 22).
15. Wikimedia Commons. File: linagliptin.png. http://commons.wikimedia.org/wiki/File:Linagliptin.png (accessed 2011 Jul 23).
16. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihy-dropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP- 4 inhibitor for the treatment of type 2 dia- betes. J Med Chem 2007;50:6450-3. DOI 10.1021/jm701280z
17. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase- 4 inhibitors. J Pharmacol Exp Ther 2008;325:175-82.DOI 10.1124/jpet.107.135723
18. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolera-bility, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8. DOI 10.1177/0091270008323753
19. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase- 4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786-94.DOI 10.1111/j.1463-1326.2009.01046.x
20. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase- 4 in-hibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78. DOI 10.1124/dmd.109.031476
21. Gräefe-Mody U, Rose P, Ring A, Waldhauser L, Cinca R, Woerle H-J. The novel DPP- 4 inhibitor linagliptin can be administered to patients with various degrees of hepatic impairment without dose adjustment (ab- stract). J Diabetes 2011;3(suppl 1):220.
22. Gräefe-Mody U, Friedrich C, Port A. Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in type 2 diabetes patients with renal impairment (abstract). Presented at: 46th Annual Meeting of the European Associ- ation for the Study of Diabetes (EASD), Stockholm, Sweden, September 20-24, 2010.
23. Product information. Tradjenta (linagliptin). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., July 2011.
24. Cooper M, von Eynatten M, Emser A, Patel S, Woerle H-J. Efficacy and safety of linagliptin in patients with type 2 diabetes, with and without renal impairment: results from a global Phase III program. Presented at: 71st Scientific Sessions of the American Diabetes Association (ADA), San Diego, CA, June 24-28, 2011. 2011;60(suppl 1):A293.
25. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP- 4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Dia- bet Med 2010;27:1409-19. DOI 10.1111/j.1464-5491.2010.03131.x
26. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 dia- betes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74. DOI 10.1111/j.1463-1326.2010.01326.x
27. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a com- bination of metformin and sulfonylurea: a 24-week randomized study. Dia- bet Med 2011;28:1352-61. DOI 10.1111/j.1464-5491.2011.03387.x
28. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in pa- tients with inadequately controlled type 2 diabetes: a randomized, double- blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-61. DOI 10.1111/j.1463-1326.2011.01391.x
29. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67.DOI 10.1111/j.1463-1326.2010.01350.x
30. Bailey CJ, Green BD, Flatt PR. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Expert Opin Investig Drugs 2010;19:1017-25. DOI 10.1517/13543784.2010.505235
31. Johansen OE, Neubacher D, Von Eynatten M, Patel S, Woerle HJ. Cardiovascular risk with linagliptin in patients with type 2 diabetes: a pre-specified, prospective, and adjudicated meta-analysis from a large phase III program. Presented at: 71st Scientific Sessions of the American Diabetes Association (ADA), San Diego, CA, June 24-28, 2011. Diabetes 2011;60(suppl 1):LB9.
32. US Department of Health and Human Services. Sitagliptin (marketed as Januvia and Janumet)-acute pancreatitis. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm (accessed 2011 Aug 17).
33. Scheen AJ. Dipeptidylpeptidase- 4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88.DOI 10.2165/11532980-000000000-00000
34. Gräefe-Mody EU, Friedrich C, Brand T. Linagliptin has no pharmacokinetic interactions with commonly prescribed oral antidiabetes drugs (abstract). Presented at: 3rd World Congress on Controversies to Consensus in Dia- betes, Obesity, and Hypertension (CODHy), Prague, Czech Republic, May 13-16, 2010.
35. Gräefe-Mody EU, Friedrich C, Brand T. Linagliptin has no pharmacokinetic interactions with drugs commonly used in patients with cardiac disorders (abstract). Presented at: 3rd World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy), Prague, Czech Republic, May 13-16, 2010.
36. Friedrich C, Ring A, Brand T, Sennewald R, Gräefe-Mody EU, Woerle HJ. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011;36:17-24. DOI 10.1007/s13318-011-0028-y
37. Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010;48:367-74.
38. Friedrich C, Ring A, Port A, Gräefe-Mody U, Woerle H. Linagliptin does not alter the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon) in healthy adult female subjects (abstract PI-68). Presented at: 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 17-20, 2010.
39. Rendell M, Chrysant SG, Emser A, et al. Linagliptin effectively reduces blood glucose independent of age in patients with type 2 diabetes (ab- stract P3- 497). Presented at: 93rd Annual Meeting and Expo of The En- docrine Society (ENDO), Boston, MA, June 4-7, 2011.
40. Rendell M, Chrysant SG, Emse/xnamexr/x/namex A, et al. Linagliptin improves glycemic control independent of gender in patients with type 2 diabetes (abstract P3- 483). Presented at: 93rd Annual Meeting and Expo of The Endocrine Society (ENDO), Boston, MA, June 4-7, 2011.
41. Sloan L, Newman J, Sauce C, Von Eynatten M, Patel S, Woerle HJ. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Presented at: 71st Scientific Sessions of the American Di- abetes Association (ADA), San Diego, CA, June 24-28, 2011. Diabetes 2011;60(suppl 1):A114.
42. Barnett A. DPP- 4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70.DOI 10.1111/j.1742-1241.2006.01178.x
43. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes, 2009. www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf (accessed 2011 Jul 23).
44. Retlich S, Duval V, Ring A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determina- tion of absolute bioavailability of the dipeptidyl peptidase- 4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 2010;49:829-40. DOI 10.2165/11536620-000000000-00000
45. Drugstore.com. www.drugstore.com (accessed 2011 Oct 17).